Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2

Journal of Pediatric Surgery

Volumn 35, Issue 6, 2000, Pages 847-851

  Alavi, Karim ^a   Schwartz, Marshall Z ^a   Palazzo, Juan P ^a   Prasad, Rajeev ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Chronic ulcerative colitis; Crohn's disease; Glucagonlike peptide 2; Growth factor; Inflammatory bowel disease

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HLA B27 ANTIGEN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; ENTERITIS; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOTHERAPY; MICROSCOPIC ANATOMY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034113232     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2000.6861     Document Type: Conference Paper

References (19)

1. 2m: An animal model of HLA-B27-associated disorders. Cell. 63:1990;1099-1112
2. Drucker D, Ehrlich P, Asa S, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide-2. Proc Natl Acad Sci USA. 93:1996;7911-7916
3. Tsai C, Hill M, Asa S, et al. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol. 273:1997;E77-E84
4. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol. 273:1997;R1965-R1971
5. Scott R, Kirk D, MacNaughton W, et al. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 275:1998;G911-G921
6. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology. 109:1995;1344-1367
7. Elaine M, Conner P, Satoshi Aiko, et al. Genetically engineered models of inflammatory bowel disease. Curr Opin Gastroenterol. 10:1994;358-364
8. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human B2-microglobulin transgenic rats. J Clin Inves. 98:1996;945-953
9. Taurog JD, Maika SD, Simmons WA, et al. Susceptibility to inflammatory disease in HLA-B27 transgenic rat line correlates with the level of B27 expression. J Immunol. 150:1993;4168-4178
10. Schwartz MZ, Storozuk RB. Can gastrointestinal hormones enhance intestinal adaptation? Surgery. 98:1985;430-435
11. Schwartz MZ, Storozuk RB. Enhancement of small intestine absorption by intraluminal gastrin. J Surg Res. 40:1986;421-425
12. Lukish J, Schwartz MZ, Rushin JM. A comparison of the effect of growth factors on intestinal function and structure in short bowel syndrome. J Pediatr Surg. 32:1997;1652-1655
13. Kato Y, Yu D, Lukish J, et al. Hepatocyte growth factor enhances intestinal mucosal cell function and mass in vivo. J Pediatr Surg. 32:1997;991-994
14. Kato Y, Yu D, Lukish J, et al. Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo. J Surg Res. 71:1997;49-53
15. Kato Y, Yu D, Schwartz MZ. Enhancement of intestinal adaptation by hepatocyte growth factor. J Pediatr Surg. 33:1998;235-239
16. Kato Y, Alavi K, Yu D, et al. Glucagon-like peptide-2 enhances intestinal function following massive small bowel resection. Gastroenterology. 114:1998;A1152
17. Kato Y, Yu D, Schwartz MZ. Glucagon-like peptide-2 enhances small intestine absorptive function and mucosal mass in vivo. J Pediatr Surg. 34:1999;18-21
18. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and crohn's disease. J Clin Immunol. 16:1996;144-150
19. van Dulleman HM, van Deventer SJH, Hommes DW, et al. Treatment of crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody. Gastroenterology. 109:1995;129-135